The University of Chicago Header Logo

Connection

Daniel Wilson to Humans

This is a "connection" page, showing publications Daniel Wilson has written about Humans.
Connection Strength

0.258
  1. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev Clin Pharmacol. 2022 May; 15(5):501-513.
    View in: PubMed
    Score: 0.027
  2. Machine learning to predict the source of campylobacteriosis using whole genome data. PLoS Genet. 2021 10; 17(10):e1009436.
    View in: PubMed
    Score: 0.026
  3. Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial. Drugs Aging. 2015 Dec; 32(12):1055-65.
    View in: PubMed
    Score: 0.017
  4. Evolutionary dynamics of Staphylococcus aureus during progression from carriage to disease. Proc Natl Acad Sci U S A. 2012 Mar 20; 109(12):4550-5.
    View in: PubMed
    Score: 0.013
  5. Prevalence and coexistence of cardiovascular comorbidities among the US dyslipidemic population aged = 65 years by lipid-lowering medication use status. Postgrad Med. 2010 Sep; 122(5):142-9.
    View in: PubMed
    Score: 0.012
  6. Rapid evolution and the importance of recombination to the gastroenteric pathogen Campylobacter jejuni. Mol Biol Evol. 2009 Feb; 26(2):385-97.
    View in: PubMed
    Score: 0.011
  7. Tracing the source of campylobacteriosis. PLoS Genet. 2008 Sep 26; 4(9):e1000203.
    View in: PubMed
    Score: 0.010
  8. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022 01; 33(1):225-237.
    View in: PubMed
    Score: 0.006
  9. 4,7-Disubstituted 7H-Pyrrolo[2,3-d]pyrimidines and Their Analogs as Antiviral Agents against Zika Virus. Molecules. 2021 Jun 22; 26(13).
    View in: PubMed
    Score: 0.006
  10. Discovery of Irreversible p97 Inhibitors. J Med Chem. 2019 03 14; 62(5):2814-2829.
    View in: PubMed
    Score: 0.005
  11. 6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. Eur J Med Chem. 2018 Aug 05; 156:652-665.
    View in: PubMed
    Score: 0.005
  12. 6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H. Eur J Med Chem. 2018 Aug 05; 156:680-691.
    View in: PubMed
    Score: 0.005
  13. Bayesian reconstruction of transmission within outbreaks using genomic variants. PLoS Comput Biol. 2018 04; 14(4):e1006117.
    View in: PubMed
    Score: 0.005
  14. Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity. J Med Chem. 2017 06 22; 60(12):5045-5056.
    View in: PubMed
    Score: 0.005
  15. Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. J Hypertens. 2017 05; 35 Suppl 1:S57-S63.
    View in: PubMed
    Score: 0.005
  16. 6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase. Eur J Med Chem. 2017 Mar 10; 128:168-179.
    View in: PubMed
    Score: 0.005
  17. 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H. J Med Chem. 2016 07 14; 59(13):6136-48.
    View in: PubMed
    Score: 0.004
  18. Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H. J Med Chem. 2016 05 26; 59(10):5051-62.
    View in: PubMed
    Score: 0.004
  19. 5-((3-Amidobenzyl)oxy)nicotinamides as Sirtuin 2 Inhibitors. J Med Chem. 2016 Apr 14; 59(7):2928-41.
    View in: PubMed
    Score: 0.004
  20. 3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations. J Med Chem. 2016 Mar 24; 59(6):2648-59.
    View in: PubMed
    Score: 0.004
  21. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study). Am J Cardiol. 2016 Apr 15; 117(8):1199-205.
    View in: PubMed
    Score: 0.004
  22. Rapid host switching in generalist Campylobacter strains erodes the signal for tracing human infections. ISME J. 2016 Mar; 10(3):721-9.
    View in: PubMed
    Score: 0.004
  23. Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. J Med Chem. 2014 Oct 23; 57(20):8340-57.
    View in: PubMed
    Score: 0.004
  24. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct; 45(10):2974-82.
    View in: PubMed
    Score: 0.004
  25. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med. 2013 Sep 26; 369(13):1195-205.
    View in: PubMed
    Score: 0.004
  26. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). Am J Cardiol. 2012 Jun 15; 109(12):1761-6.
    View in: PubMed
    Score: 0.003
  27. Utilizing a combination of molecular and spatial tools to assess the effect of a public health intervention. Prev Vet Med. 2011 Dec 01; 102(3):242-53.
    View in: PubMed
    Score: 0.003
  28. Evolution of an agriculture-associated disease causing Campylobacter coli clade: evidence from national surveillance data in Scotland. PLoS One. 2010 Dec 15; 5(12):e15708.
    View in: PubMed
    Score: 0.003
  29. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure. Bioorg Med Chem. 2010 Aug 15; 18(16):5950-64.
    View in: PubMed
    Score: 0.003
  30. Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis. J Med Chem. 2010 Jun 24; 53(12):4768-78.
    View in: PubMed
    Score: 0.003
  31. Spatio-temporal epidemiology of Campylobacter jejuni enteritis, in an area of Northwest England, 2000-2002. Epidemiol Infect. 2010 Oct; 138(10):1384-90.
    View in: PubMed
    Score: 0.003
  32. Molecular and spatial epidemiology of human campylobacteriosis: source association and genotype-related risk factors. Epidemiol Infect. 2010 Oct; 138(10):1372-83.
    View in: PubMed
    Score: 0.003
  33. Assigning the source of human campylobacteriosis in New Zealand: a comparative genetic and epidemiological approach. Infect Genet Evol. 2009 Dec; 9(6):1311-9.
    View in: PubMed
    Score: 0.003
  34. Broad-scale recombination patterns underlying proper disjunction in humans. PLoS Genet. 2009 Sep; 5(9):e1000658.
    View in: PubMed
    Score: 0.003
  35. Campylobacter genotyping to determine the source of human infection. Clin Infect Dis. 2009 Apr 15; 48(8):1072-8.
    View in: PubMed
    Score: 0.003
  36. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009 May; 53(5):741-50.
    View in: PubMed
    Score: 0.003
  37. Inhibition of siderophore biosynthesis by 2-triazole substituted analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: antibacterial nucleosides effective against Mycobacterium tuberculosis. J Med Chem. 2008 Dec 11; 51(23):7495-507.
    View in: PubMed
    Score: 0.003
  38. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens. 2009 Feb; 22(2):137-44.
    View in: PubMed
    Score: 0.003
  39. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008 Aug; 83(8):870-9.
    View in: PubMed
    Score: 0.003
  40. Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008 Aug 01; 16(15):7462-9.
    View in: PubMed
    Score: 0.003
  41. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008 Apr 15; 51(15):1448-54.
    View in: PubMed
    Score: 0.003
  42. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007 Nov; 2(6):1131-9.
    View in: PubMed
    Score: 0.002
  43. Methylenebis(sulfonamide) linked nicotinamide adenine dinucleotide analogue as an inosine monophosphate dehydrogenase inhibitor. Bioorg Med Chem Lett. 2007 Jun 01; 17(11):3152-5.
    View in: PubMed
    Score: 0.002
  44. Evolution of the human immunodeficiency virus envelope gene is dominated by purifying selection. Genetics. 2006 Nov; 174(3):1441-53.
    View in: PubMed
    Score: 0.002
  45. Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1. BMC Evol Biol. 2006 Mar 23; 6:28.
    View in: PubMed
    Score: 0.002
  46. The influence of mutation, recombination, population history, and selection on patterns of genetic diversity in Neisseria meningitidis. Mol Biol Evol. 2005 Mar; 22(3):562-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.